A Randomized Double-blind, Four-Arm Active and Placebo-controlled Dose-Finding Trial to Evaluate the Efficacy, Tolerability, Safety and Dose Response of LYT-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Latest Information Update: 23 May 2025
At a glance
- Drugs Deupirfenidone (Primary) ; Pirfenidone
- Indications Idiopathic pulmonary fibrosis
- Focus Registrational; Therapeutic Use
- Acronyms ELEVATE; ELEVATE IPF
- Sponsors PureTech Health
Most Recent Events
- 20 May 2025 Results presented in a PureTech Health Media Release.
- 20 May 2025 According to a PureTech Health Media Release, data from this study presented at the 2025 American Thoracic Society (ATS) International Conference in San Francisco.
- 01 May 2025 Status changed from active, no longer recruiting to completed.